Novartis
Executives at Swiss firms increase share purchases amid market declines
Management teams at Partners Group, Stadler Rail, EFG International, Medacta and Warteck Invest step up insider buying as share prices face varying pressures.
SMI's 47.4% Concentration in Three Stocks Highlights Risk
Novartis's recent double-digit drop exposes concentration risks in the Swiss Market Index, where three heavyweights hold a nearly half-share.
Swiss Heavyweights Outperform SMI as Markets Await Quarterly Earnings
Nestlé, Novartis, and Roche finished the week ahead of the Swiss Market Index, with investors now turning their attention to upcoming quarterly reports.
Swiss Market Index Closes Higher as Bond Yields and Oil Prices Decline
The Swiss stock exchange ended the session with gains, driven by lower bond yields and crude oil prices, while Wall Street indexes reached record highs.
Why Biogen, Novartis and NurExone Target the Orphan Drug Pathway
Regulatory incentives for rare diseases offer distinct commercial frameworks in the US and Europe, shaping development pathways for pharmaceutical and biotech firms.